| scholarly article | Q13442814 |
| P50 | author | Dimitrios P Kontoyiannis | Q88469665 |
| P2093 | author name string | Nikolaos V Sipsas | |
| P2860 | cites work | Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients | Q24244555 |
| Candida colonization and subsequent infections in critically ill surgical patients | Q24535524 | ||
| Recent advances in the management of mucormycosis: from bench to bedside | Q24642450 | ||
| Epidemiological trends in nosocomial candidemia in intensive care | Q25255762 | ||
| Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature | Q28243864 | ||
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans | Q28265703 | ||
| β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis | Q83514901 | ||
| Ocular manifestations of candidemia | Q84566817 | ||
| Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial | Q28278518 | ||
| NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 | Q28298371 | ||
| Invasive aspergillosis in the intensive care unit | Q28306909 | ||
| Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions | Q29399166 | ||
| Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis | Q33229934 | ||
| Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry | Q33445758 | ||
| Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database | Q33826372 | ||
| Special pharmacokinetics of fluconazole in septic, obese and burn patients. | Q33949797 | ||
| PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. | Q33960914 | ||
| Comparison of albicans vs. non-albicans candidemia in French intensive care units | Q34026915 | ||
| Management of Candida species infections in critically ill patients | Q34280580 | ||
| Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases | Q34404335 | ||
| Epidemiology and outcome of zygomycosis: a review of 929 reported cases | Q34440240 | ||
| Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting | Q34487665 | ||
| Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients | Q34529026 | ||
| Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 | ||
| Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 | ||
| The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts | Q35019932 | ||
| Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study | Q35530416 | ||
| Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients | Q35923365 | ||
| Combination therapy for invasive mycoses: evaluation of past clinical trial designs | Q35951634 | ||
| Is it time to abandon the use of amphotericin B bladder irrigation? | Q36103620 | ||
| Diagnosis of disseminated candidiasis by measurement of urine D-arabinitol/L-arabinitol ratio | Q36537655 | ||
| Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. | Q36655030 | ||
| Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome | Q36686780 | ||
| Time to blood culture positivity as a marker for catheter-related candidemia | Q36747533 | ||
| Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting | Q36749310 | ||
| Candiduria in intensive care units: association with heavy colonization and candidaemia. | Q36850910 | ||
| Association of fluconazole pharmacodynamics with mortality in patients with candidemia | Q36870712 | ||
| Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. | Q37344532 | ||
| Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit | Q37559826 | ||
| Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. | Q40414348 | ||
| Design of efficacy trials of cytokines in combination with antifungal drugs. | Q40467837 | ||
| Dermatologic manifestations of infections in neutropenic patients. | Q40565204 | ||
| Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management | Q41550049 | ||
| Identification of Candida albicans and Candida glabrata within 1.5 hours directly from positive blood culture bottles with a shortened peptide nucleic acid fluorescence in situ hybridization protocol | Q42090000 | ||
| Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death | Q43142736 | ||
| Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. | Q43170662 | ||
| Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection | Q43438479 | ||
| Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study | Q43556141 | ||
| Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit | Q43571511 | ||
| Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit | Q43737173 | ||
| Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. | Q43823539 | ||
| Risk factors for albicans and non-albicans candidemia in the intensive care unit | Q43875871 | ||
| Management of central venous catheters in patients with cancer and candidemia | Q43877465 | ||
| Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? | Q44171879 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. | Q44272491 | ||
| Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections | Q44417870 | ||
| A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. | Q44440960 | ||
| Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm | Q44459959 | ||
| Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy | Q44517533 | ||
| Voriconazole salvage treatment of invasive candidiasis. | Q44621426 | ||
| Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome | Q45061279 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients | Q45187465 | ||
| Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. | Q45923797 | ||
| A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. | Q46023744 | ||
| Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). | Q46072663 | ||
| Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study | Q47583016 | ||
| Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence | Q47997226 | ||
| Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. | Q51181941 | ||
| Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. | Q51185547 | ||
| The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. | Q51188122 | ||
| Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. | Q51661215 | ||
| Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. | Q51793152 | ||
| A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. | Q51948770 | ||
| Reversed halo sign in invasive pulmonary fungal infections. | Q53422291 | ||
| Medical imaging and timely diagnosis of invasive pulmonary aspergillosis. | Q53505452 | ||
| Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. | Q54063081 | ||
| Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trials | Q56970479 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis | Q57208491 | ||
| Galactomannan in Bronchoalveolar Lavage Fluid | Q57559940 | ||
| Combined detection of mannanaemia and anti-mannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species | Q59412889 | ||
| Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study | Q61833672 | ||
| Echinocandin‐Based Initial Therapy in Fungemic Patients with Cancer: A Focus on Recent Guidelines of the Infectious Diseases Society of America | Q64132738 | ||
| Severe candidal infections in neutropenic patients | Q72690329 | ||
| Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group | Q73321118 | ||
| Comparison of premortem clinical diagnoses in critically iII patients and subsequent autopsy findings | Q73892686 | ||
| Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey | Q74065829 | ||
| Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients | Q76390402 | ||
| Pulmonary candidiasis in patients with cancer: an autopsy study | Q77440601 | ||
| Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study | Q80382945 | ||
| Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients | Q82548092 | ||
| P433 | issue | 6 | |
| P921 | main subject | intensive care unit | Q5094647 |
| invasive fungal infections | Q55022218 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 464-471 | |
| P577 | publication date | 2012-02-14 | |
| P1433 | published in | International Journal of Antimicrobial Agents | Q15724616 |
| P1476 | title | Invasive fungal infections in patients with cancer in the Intensive Care Unit | |
| P478 | volume | 39 |
| Q41555412 | Analysis of the essentiality of ROM2 genes in the pathogenic yeasts Candida glabrata and Candida albicans using temperature-sensitive mutants |
| Q54263493 | Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B. |
| Q100672119 | Broad-Spectrum Antifungal Agents: Fluorinated Aryl- and Heteroaryl-Substituted Hydrazones |
| Q33851382 | Detection of galactomannan in bronchoalveolar lavage of the intensive care unit patients at risk for invasive aspergillosis |
| Q34158642 | Immunoproteome of Aspergillus fumigatus using sera of patients with invasive aspergillosis |
| Q39206915 | Invasive mould infections in the ICU setting: complexities and solutions |
| Q56884992 | Phage vaccines displaying YGKDVKDLFDYAQE epitope induce protection against systemic candidiasis in mouse model |
| Q90114163 | SUMOylation in Human Pathogenic Fungi: Role in Physiology and Virulence |
| Q28829066 | Shedding light on Aspergillus niger volatile exometabolome |
| Q90283978 | Studying fungal pathogens of humans and fungal infections: fungal diversity and diversity of approaches |
| Q30658189 | Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. |
| Q31136511 | The Candida Genome Database (CGD): incorporation of Assembly 22, systematic identifiers and visualization of high throughput sequencing data |
| Q37661839 | The Candida Genome Database: the new homology information page highlights protein similarity and phylogeny |
| Q28066328 | The prognostic factors for patients with hematological malignancies admitted to the intensive care unit |
| Q37041868 | Ultrasensitive rapid detection of human serum antibody biomarkers by biomarker-capturing viral nanofibers. |
Search more.